The P-III (STARGLO) trial is to find the safety, tolerability & efficacy of Columvi + gemcitabine & oxaliplatin (GemOx) vs rituximab + GemOx to treat r/r DLBCL patients administered with at least 1L of therapy & not eligible for autologous stem cell transplant. Trial aims at gaining full approval in the US & EU
The study, at 11.3mos. of median follow-up, reached the 1EP of OS showing reduced death risk by 41% with mOS not attained vs 9mos.
The study also reached the 2EPs, depicting PFS of 63%; mOS was 25.5mos. vs 12.9mos. and CR was observed in 58.5% vs 25.3% of patients at a median follow-up of 20.7mos. (patients completed the treatment). Data to be submitted with the regulatory authorities worldwide
Ref: Roche | Image: Roche
Related News:- Roche Reports Data from the P-III Clinical Evaluation of Columvi to Treat R/R Diffuse Large B-cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
